
    
      This is an open-label, single-arm, interventional multi-center study designed to explore ITI
      performed with recombinant coagulation factor VIII Fc fusion protein (rFVIIIFc) within a
      timeframe of 60 weeks in patients with severe haemophilia A, who have failed previous
      attempts at tolerization including use of immunosuppressants.
    
  